CROS NT, the international contract research organisation (CRO) based in Italy and specialising in clinical-data services, has marked its second acquisition in six months by taking over UK company MDSL International, a niche CRO that provides biometrics services such as clinical-data management and statistical input to the pharmaceutical industry.
Founded by the executive chairman Dr Edmund Otun in April 1996, MDSL is privately held, with a head office in the Maidenhead area of Berkshire, UK. Financial details of the transaction, which follows CROS NT’s acquisition of US counterpart Stat-Tech Services last September, remain confidential.
The deal adds resources to the existing CROS NT Ltd operation in the UK as well as providing new headquarters for the UK company in Maidenhead, CROS NT noted.
“We are adding a highly experienced team to the business and further diversifying our customer base – both important objectives of the CROS NT Group,” commented Andrew MacGarvey, who took over from Paolo Morelli (now CROS NT chairman) as the group’s chief executive officer and president on 1 January.
“We will move our UK headquarters to Maidenhead, giving us a great location in terms of ongoing recruitment and access by our customers given its proximity to London,” MacGarvey added.
Together with the acquisition of Stat-Tech Services, the latest deal “demonstrates our commitment to place expertise close to our customers and to grow to meet the increasing demand for our services”, he said.
According to Otun, who will remain with the merged company providing consultancy services to emerging companies that want advice on getting their products to market or securing licensing deals, the acquisition will enable the MDSL to offer expanded resources to existing clients – “something they have been asking for”.
Jo Marshall, managing director of MDSL International, becomes UK country manager for CROS NT Ltd.
“In addition to giving us greater critical mass here in the UK, this deal will give our existing customers access to the CROS NT technology portfolio which includes several electronic data-capture platforms, a clinical-trial management system, and electronic patient-reported outcomes solutions,” Marshall pointed out.